Can You Use Low-Dose Testosterone with a PFO?
Yes, low-dose testosterone therapy can be used in patients with a patent foramen ovale (PFO), but requires careful risk assessment and monitoring for venous thromboembolism (VTE), as testosterone increases thrombotic risk which could theoretically lead to paradoxical embolism through the PFO.
Key Thrombotic Risk Considerations
The primary concern with testosterone therapy in PFO patients relates to venous thromboembolism risk:
Testosterone therapy increases VTE risk: FDA labeling explicitly warns that "venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients using testosterone products" 1.
PFO creates paradoxical embolism risk: In patients with massive PE, the presence of a PFO increases the risk of death (relative risk 2.4), ischemic stroke (relative risk 5.9), and peripheral arterial embolism (relative risk 15) through paradoxical embolization 2.
The mechanism matters: A PFO provides an anatomic substrate for paradoxical embolization of thrombus, where venous clots can bypass the lungs and enter the arterial circulation 3.
Evidence on Testosterone and Thrombotic Events
Recent large-scale evidence provides reassurance but not complete safety:
The TRAVERSE trial and recent meta-analyses show testosterone therapy does not significantly increase major adverse cardiovascular events in appropriately selected patients 4.
VTE risk is real but quantifiable: A 2025 study found testosterone therapy in cis men with hypogonadism was associated with higher risks of acute pulmonary embolism/deep vein thrombosis (HR 1.26 [1.18-1.34], P < .0001) 5.
Hematocrit elevation is consistent: Testosterone significantly increases hemoglobin (weighted mean difference 0.80 g/dl) and hematocrit (3.18%), which contributes to thrombotic risk 6.
Clinical Decision Algorithm
Step 1: Assess PFO Risk Stratification
Determine if the PFO is high-risk for paradoxical embolism:
High-risk PFO features include: large shunt size, atrial septal aneurysm, history of cryptogenic stroke, or prior paradoxical embolism 2, 7.
Low-risk PFO: Incidentally discovered, small shunt, no history of stroke or systemic embolism 8.
Step 2: Evaluate Testosterone Indication Strength
Strong indication: Confirmed hypogonadism with symptoms significantly impacting quality of life, documented low testosterone on two separate morning measurements 9, 1.
Weak indication: Age-related low testosterone without clear symptoms (note: safety not established in this population per FDA labeling) 1.
Step 3: Apply Risk-Benefit Framework
For LOW-RISK PFO (asymptomatic, small shunt):
- Testosterone therapy is reasonable with standard monitoring 8, 10.
- Monitor hematocrit regularly; maintain <54% to minimize VTE risk 1, 6.
- Consider antiplatelet therapy (aspirin 50-100 mg daily) as per guidelines for asymptomatic PFO, though evidence is weak 8.
For HIGH-RISK PFO (large shunt, atrial septal aneurysm, prior stroke):
- Testosterone can still be used but requires enhanced monitoring and consideration of anticoagulation 7.
- If patient has history of cryptogenic stroke with PFO, they should already be on antiplatelet therapy (aspirin 50-100 mg/d) or anticoagulation 11, 12.
- Strongly consider PFO closure before initiating testosterone if patient has had cryptogenic stroke, as closure substantially reduces recurrent stroke risk (annualized incidence 0.47% vs 1.09% with medical therapy alone, HR 0.41) 13, 14.
Step 4: Monitoring Protocol
If proceeding with testosterone therapy in a PFO patient:
- Baseline assessment: Hematocrit, hemoglobin, prostate-specific antigen, lipids 1.
- Follow-up at 14 and 28 days: Testosterone levels and hematocrit 1.
- Ongoing monitoring: Hematocrit every 3-6 months; if >54%, reduce dose or temporarily discontinue 1, 6.
- VTE surveillance: Educate patient on DVT/PE symptoms; evaluate immediately if signs develop 1.
Critical Caveats
Absolute contraindications to testosterone (regardless of PFO status):
- Active VTE or recent VTE without adequate anticoagulation 1.
- Severe untreated sleep apnea (increases VTE risk) 1.
- Uncontrolled heart failure with significant edema 1.
The PFO itself does NOT contraindicate testosterone, but it modifies the risk-benefit calculation by increasing the potential consequences of testosterone-induced VTE 2, 5.
Anticoagulation considerations: If the patient requires anticoagulation for another indication (e.g., atrial fibrillation, prior VTE), this actually provides some protection against paradoxical embolism through the PFO while on testosterone 8, 7.
Bottom Line
Low-dose testosterone therapy is not contraindicated in PFO patients, but the decision requires stratifying both the PFO risk (size, features, history) and the strength of the testosterone indication. For high-risk PFO patients, particularly those with prior cryptogenic stroke, strongly consider PFO closure before initiating testosterone therapy, as this addresses the anatomic substrate for paradoxical embolism while allowing safe hormone replacement 12, 13, 14.